Switch theme
Sign up to access all valuation multiples
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.
2008
121
LTM Revenue $38.9M
LTM EBITDA $22.2M
$188M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
EyePoint Pharmaceuticals has a last 12-month revenue of $38.9M and a last 12-month EBITDA of $22.2M.
In the most recent fiscal year, EyePoint Pharmaceuticals achieved revenue of $46.0M and an EBITDA of -$69.0M.
EyePoint Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See EyePoint Pharmaceuticals valuation multiples based on analyst estimates| FY 2022 | FY 2023 | FY 2024 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $41.4M | $46.0M | $42.6M | $38.9M | XXX |
| Gross Profit | $28.8M | $33.1M | $41.4M | XXX | XXX |
| Gross Margin | 69% | 72% | 97% | XXX | XXX |
| EBITDA | -$96.6M | -$69.0M | $23.9M | $22.2M | XXX |
| EBITDA Margin | -233% | -150% | 56% | 57% | XXX |
| Net Profit | -$58.4M | -$102M | -$70.8M | XXX | XXX |
| Net Margin | -141% | -222% | -166% | XXX | XXX |
| Net Debt | n/a | n/a | n/a | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of February 21, 2025, EyePoint Pharmaceuticals's stock price is $6.
EyePoint Pharmaceuticals has current market cap of $420M, and EV of $188M.
See EyePoint Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $188M | $420M | XXX | XXX | XXX | XXX | $-2.22 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of February 21, 2025, EyePoint Pharmaceuticals has market cap of $420M and EV of $188M.
EyePoint Pharmaceuticals's trades at 4.8x LTM EV/Revenue multiple, and 8.5x LTM EBITDA.
Analysts estimate EyePoint Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for EyePoint Pharmaceuticals and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $188M | XXX | XXX | XXX |
| EV/Revenue | 4.4x | XXX | XXX | XXX |
| EV/EBITDA | 7.9x | XXX | XXX | XXX |
| P/E | -3.5x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | -1.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpEyePoint Pharmaceuticals's NTM/LTM revenue growth is -57%
EyePoint Pharmaceuticals's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $1.0M for the same period.
Over next 12 months, EyePoint Pharmaceuticals's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate EyePoint Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for EyePoint Pharmaceuticals and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | -8% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 56% | XXX | XXX | XXX | XXX |
| EBITDA Growth | -135% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 0% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.0M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 25% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 87% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 141% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 253% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
EyePoint Pharmaceuticals acquired XXX companies to date.
Last acquisition by EyePoint Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . EyePoint Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was EyePoint Pharmaceuticals founded? | EyePoint Pharmaceuticals was founded in 2008. |
| Where is EyePoint Pharmaceuticals headquartered? | EyePoint Pharmaceuticals is headquartered in United States of America. |
| How many employees does EyePoint Pharmaceuticals have? | As of today, EyePoint Pharmaceuticals has 121 employees. |
| Who is the CEO of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals's CEO is Dr. Jay S. Duker, M.D.. |
| Is EyePoint Pharmaceuticals publicy listed? | Yes, EyePoint Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals trades under EYPT ticker. |
| When did EyePoint Pharmaceuticals go public? | EyePoint Pharmaceuticals went public in 2008. |
| Who are competitors of EyePoint Pharmaceuticals? | Similar companies to EyePoint Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals's current market cap is $420M |
| What is the current revenue of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals's last 12-month revenue is $38.9M. |
| What is the current EBITDA of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals's last 12-month EBITDA is $22.2M. |
| What is the current EV/Revenue multiple of EyePoint Pharmaceuticals? | Current revenue multiple of EyePoint Pharmaceuticals is 4.8x. |
| What is the current EV/EBITDA multiple of EyePoint Pharmaceuticals? | Current EBITDA multiple of EyePoint Pharmaceuticals is 8.5x. |
| What is the current revenue growth of EyePoint Pharmaceuticals? | EyePoint Pharmaceuticals revenue growth between 2023 and 2024 was -8%. |
| Is EyePoint Pharmaceuticals profitable? | Yes, EyePoint Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
